News Releases

$

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Hero Chart

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 24, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that it will participate in Piper Sandler’s Virtual European Association for the Study of the Liver (EASL) Takeaway Day on Monday, June 28, 2021 , at
... Read More
Additional Formats
- Data from five years of treatment with maralixibat reinforces safety and tolerability in patients with Alagille syndrome. - Intrahepatic cholestasis of pregnancy patient-reported data demonstrates significant burden of disease and underscores urgent need for new treatment options.
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 16, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced its participation in The International Liver Congress™ taking place virtually June 23-26, 2021 . The company will be presenting an integrated safety
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 191,400 shares of common stock to
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 7, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Carol L. Brosgart , M.D., clinical professor of medicine, biostatistics and epidemiology, University of California, San Francisco , as an independent director to its
... Read More
Additional Formats
- Maralixibat-treated patients achieving serum bile acid control have improved five-year native liver survival; nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology. - Safety data from more than five years of maralixibat treatment across three Phase 2 ALGS studies
... Read More
Additional Formats
- Integrated safety analysis on gastrointestinal tolerability of maralixibat in patients with Alagille syndrome presented in poster session. - Five-year analysis demonstrating improvements in transplant-free survival for patients with PFIC2 featured in oral presentation; abstract nominated for the
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--May 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 87,500 shares of common stock to 9
... Read More
Additional Formats
- NDA for maralixibat in Alagille syndrome (ALGS) granted priority review by U.S. FDA; PDUFA date is September 29, 2021 - Received additional $65.0 million in funding from Oberland Capital based on NDA acceptance - Commercial team hired in anticipation of U.S.
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that the company will report financial results for the quarter ended March 31, 2021 on Thursday, May 6, 2021 . That same day, Mirum will host a conference call and audio webcast at
... Read More
Additional Formats